These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 32771227)

  • 1. Defining the undetectable: The current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity.
    Diamond BT; Rustad E; Maclachlan K; Thoren K; Ho C; Roshal M; Ulaner GA; Landgren CO
    Blood Rev; 2021 Mar; 46():100732. PubMed ID: 32771227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MRD Assessment in Multiple Myeloma: Progress and Challenges.
    Bertamini L; D'Agostino M; Gay F
    Curr Hematol Malig Rep; 2021 Apr; 16(2):162-171. PubMed ID: 33950462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive characterization of circulating and bone marrow-derived multiple myeloma cells at minimal residual disease.
    Waldschmidt JM; Anand P; Knoechel B; Lohr JG
    Semin Hematol; 2018 Jan; 55(1):33-37. PubMed ID: 29759150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minimal residual disease in multiple myeloma: defining the role of next generation sequencing and flow cytometry in routine diagnostic use.
    Maclachlan KH; Came N; Diamond B; Roshal M; Ho C; Thoren K; Mayerhoefer ME; Landgren O; Harrison S
    Pathology; 2021 Apr; 53(3):385-399. PubMed ID: 33674146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measurable Residual Disease and Decision-Making in Multiple Myeloma.
    Derman BA; Fonseca R
    Hematol Oncol Clin North Am; 2024 Apr; 38(2):477-495. PubMed ID: 38184470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple Myeloma Minimal Residual Disease Detection: Targeted Mass Spectrometry in Blood vs Next-Generation Sequencing in Bone Marrow.
    Langerhorst P; Noori S; Zajec M; De Rijke YB; Gloerich J; van Gool AJ; Caillon H; Joosten I; Luider TM; Corre J; VanDuijn MM; Dejoie T; Jacobs JFM
    Clin Chem; 2021 Nov; 67(12):1689-1698. PubMed ID: 34643690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Chinese expert consensus on minimal residual disease detection in multiple myeloma based on bone marrow samples (2024)].
    ;
    Zhonghua Xue Ye Xue Za Zhi; 2024 Jun; 45(6):534-541. PubMed ID: 39134483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minimal residual disease analysis in myeloma - when, why and where.
    Yanamandra U; Kumar SK
    Leuk Lymphoma; 2018 Aug; 59(8):1772-1784. PubMed ID: 29019452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration.
    Anderson KC; Auclair D; Adam SJ; Agarwal A; Anderson M; Avet-Loiseau H; Bustoros M; Chapman J; Connors DE; Dash A; Di Bacco A; Du L; Facon T; Flores-Montero J; Gay F; Ghobrial IM; Gormley NJ; Gupta I; Higley H; Hillengass J; Kanapuru B; Kazandjian D; Kelloff GJ; Kirsch IR; Kremer B; Landgren O; Lightbody E; Lomas OC; Lonial S; Mateos MV; Montes de Oca R; Mukundan L; Munshi NC; O'Donnell EK; Orfao A; Paiva B; Patel R; Pugh TJ; Ramasamy K; Ray J; Roshal M; Ross JA; Sigman CC; Thoren KL; Trudel S; Ulaner G; Valente N; Weiss BM; Zamagni E; Kumar SK
    Clin Cancer Res; 2021 Oct; 27(19):5195-5212. PubMed ID: 34321279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials.
    Costa LJ; Derman BA; Bal S; Sidana S; Chhabra S; Silbermann R; Ye JC; Cook G; Cornell RF; Holstein SA; Shi Q; Omel J; Callander NS; Chng WJ; Hungria V; Maiolino A; Stadtmauer E; Giralt S; Pasquini M; Jakubowiak AJ; Morgan GJ; Krishnan A; Jackson GH; Mohty M; Mateos MV; Dimopoulos MA; Facon T; Spencer A; Miguel JS; Hari P; Usmani SZ; Manier S; McCarthy P; Kumar S; Gay F; Paiva B
    Leukemia; 2021 Jan; 35(1):18-30. PubMed ID: 32778736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minimal residual disease in multiple myeloma: why, when, where.
    Yee AJ; Raje N
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):37-45. PubMed ID: 34889430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Best practices for the assessment of measurable residual disease (MRD) in multiple myeloma.
    Bal S; Costa LJ
    Clin Adv Hematol Oncol; 2020 Jan; 18 Suppl 1(1):1-20. PubMed ID: 33843859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minimal Residual Disease Detection by Flow Cytometry in Multiple Myeloma: Why and How?
    Roshal M
    Semin Hematol; 2018 Jan; 55(1):4-12. PubMed ID: 29759152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma.
    Ching T; Duncan ME; Newman-Eerkes T; McWhorter MME; Tracy JM; Steen MS; Brown RP; Venkatasubbarao S; Akers NK; Vignali M; Moorhead ME; Watson D; Emerson RO; Mann TP; Cimler BM; Swatkowski PL; Kirsch IR; Sang C; Robins HS; Howie B; Sherwood A
    BMC Cancer; 2020 Jun; 20(1):612. PubMed ID: 32605647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upgraded Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma.
    Yao Q; Bai Y; Orfao A; Kumar S; Chim CS
    J Mol Diagn; 2020 May; 22(5):679-684. PubMed ID: 32151713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications.
    Anderson KC; Auclair D; Kelloff GJ; Sigman CC; Avet-Loiseau H; Farrell AT; Gormley NJ; Kumar SK; Landgren O; Munshi NC; Cavo M; Davies FE; Di Bacco A; Dickey JS; Gutman SI; Higley HR; Hussein MA; Jessup JM; Kirsch IR; Little RF; Loberg RD; Lohr JG; Mukundan L; Omel JL; Pugh TJ; Reaman GH; Robbins MD; Sasser AK; Valente N; Zamagni E
    Clin Cancer Res; 2017 Aug; 23(15):3980-3993. PubMed ID: 28428191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Capture Rate of V(D)J Sequencing for Minimal Residual Disease Detection in Multiple Myeloma.
    Hultcrantz M; Rustad EH; Yellapantula V; Jacob A; Akhlaghi T; Korde N; Mailankody S; Lesokhin AM; Hassoun H; Smith EL; Lahoud OB; Landau HJ; Shah GL; Scordo M; Chung DJ; Giralt S; Papaemmanuil E; Landgren O
    Clin Cancer Res; 2022 May; 28(10):2160-2166. PubMed ID: 35553646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minimal Residual Disease in Multiple Myeloma: Potential for Blood-Based Methods to Monitor Disease.
    O'Brien A; O'Halloran F; Mykytiv V
    Clin Lymphoma Myeloma Leuk; 2022 Jan; 22(1):e34-e40. PubMed ID: 34470720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of plasma cell myeloma minimal residual disease testing by flow cytometry in an international inter-laboratory study: Is it ready for primetime use?
    Scott SD; Fletcher M; Whitehouse H; Whitby L; Yuan C; Mazzucchelli S; Lin P; de Tute R; Dorwal P; Wallace PK; Tembhare P; Arroz M; Snowden JA; Chantry AD; Barnett D
    Cytometry B Clin Cytom; 2019 May; 96(3):201-208. PubMed ID: 30565840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimal Residual Disease in Multiple Myeloma: an Important Tool in Clinical Trials.
    Gozzetti A; Bocchia M
    Rev Recent Clin Trials; 2022; 17(1):9-10. PubMed ID: 34814822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.